elosulfase alfa - Generic Medications

Elosulfase alfa is a purified human enzyme produced by recombinant DNA technology in a Chinese hamster ovary cell line. Human N-acetylgalactosamine-6-sulfatase (EC 3.1.6.4) is a hydrolytic lysosomal glycosaminoglycan-specific enzyme that hydrolyzes sulfate from either galactose-6-sulfate or N-acetyl-galactosamine-6-sulfate on the non-reducing ends of the glycosaminoglycans keratan sulfate (KS) and chondroitin-6-sulfate (C6S). Elosulfase alfa is a soluble glycosylated dimeric protein with two oligosaccharide chains per monomer. Each monomeric peptide chain contains 496 amino acids and has an approximate molecular mass of 55 kDa (59 kDa including the oligosaccharides). One of the oligosaccharide chains contains bis-mannose-6-phosphate (bisM6P). bisM6P binds a receptor at the cell surface and the binding mediates cellular uptake of the protein to the lysosome. Elosulfase alfa has a specific activity of 2.6 to 6.0 units/mg. One activity unit is defined as the amount of the enzyme required to convert 1 micromole of sulfated monosaccharide substrate D-galactopyranoside-6-sulfate (Gal-6S) to de-sulfated-galactose (Gal) and free sulfate per minute at 37°C. VIMIZIM (elosulfase alfa) injection is a sterile, preservative-free, nonpyrogenic, clear to slightly opalescent, colorless to pale yellow solution for intravenous infusion after dilution. Each single-dose vial contains 5 mL solution of 5 mg elosulfase alfa, 31.6 mg arginine hydrochloride, 34.5 mg monobasic sodium phosphate, 0.5 mg polysorbate 20, 8.2 mg sodium acetate, and 100 mg sorbitol in Water for Injection, USP with a pH between 5 to 5.8.